Abstract 1086: Predictors Of Recurrence And Retreatment In Chronic Subdural Hematoma: Secondary Analysis Of The MEMBRANE Study
Abstract
Introduction/Purpose: MEMBRANE was a randomized clinical trial (NCT04816591) to evaluate the safety and effectiveness of middle meningeal artery embolization (MMAE) using TRUFILL n-BCA in patients presenting with a subacute or chronic subdural hematoma (cSDH) as an adjunct to standard of care (SOC) compared to SOC alone. This post hoc analysis evaluates potential predictors of recurrence or retreatment which may predispose patients to treatment failure. Methods: MEMBRANE patients with symptomatic SDH were stratified by surgical or non-surgical medical management (NSMM) based on neurological assessment (with more severely affected patients requiring surgical evacuation) and randomized within each cohort to treatment with or without adjunctive embolization. Participants with 6-month follow-up, and those with recurrence/repeat intervention through 6 months, were included in this analysis. The dataset was dichotomized by recurrence/repeat intervention versus no recurrence/repeat intervention within 6 months. Multivariable logistic regression analysis was performed to estimate the odds of recurrence/repeat intervention. Results: There were 45 patients in the recurrence/repeat intervention group (60% surgical; 40% NSMM) and 242 patients in the group not requiring recurrence/repeat intervention (74.8% surgical; 25.2% NSMM). Across the analysis population, rates of recurrence/repeat intervention were 13.0% in the surgical group (surgery+MMAE, 8.2%; surgery alone, 18.4%) and 22.8% in the NSMM group (NSMM+MMAE, 17.5%; NSMM alone, 28.2%). Baseline demographics were similar between groups with or without recurrence/repeat intervention. For baseline variables that differed significantly between groups (P<0.05), multivariable analysis revealed higher odds of recurrence/repeat intervention in patients with higher screening cSDH volume, diabetes, and potentially, lower Mini-Mental State Exam (MMSE) scores (Figure 1A). This direction was maintained when adjusted for treatment pathway (Figure 1B) and was statistically significant for screening cSDH volume but not for diabetes or MMSE score. Patients receiving surgical treatment demonstrated significantly lower odds of recurrence/repeat intervention when adjusted for screening cSDH volume, MMSE score, and diabetes (OR, 0.149; 95% CI, 0.049-0.448; P=0.0007; Figure 1B). Conclusions: Analyses revealed certain predisposing factors that may be associated with cSDH recurrence or need for repeat intervention. A patient-level meta-analysis involving a larger cohort of patients with recurrence/repeat intervention could provide further insights to better inform patient selection, risk stratification, and optimal treatment strategies.